Download PDF
CC BY-NC-ND 4.0 · J Pediatr Infect Dis
DOI: 10.1055/s-0044-1800820
Original Article

Construction and Validation of an Early Identification Model for Refractory Mycoplasma pneumoniae-Positive Lobar Pneumonia

Bi Zhou    *
1   Department of Pediatric, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China
,
XiaoDong Tang   *
1   Department of Pediatric, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China
,
DaWei Mi   *
2   Department of Stomatology, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China
,
Ying Li   *
1   Department of Pediatric, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China
,
HaiYan Liu
1   Department of Pediatric, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China
,
Feng Zhu
1   Department of Pediatric, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China
› Author Affiliations Funding This work was supported by the self-funded projects supported by the Suzhou Science and Technology Bureau (SZZCZJ202328).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective This study analyzed the relationship between clinical parameters and prognosis in children with Mycoplasma pneumoniae (MP)-positive lobar pneumonia and developed an early identification model.

Methods Relevant clinical parameters were collected. Patients were then categorized into two groups based on their length of hospital stay: 116 cases in the refractory group (≥10 days) and 94 cases in the non-refractory group (<10 days). A univariate analysis of variance and binary logistic regression were utilized to develop a predictive model, accompanied by the construction of a nomogram. The model's performance was assessed using receiver operating characteristic (ROC) curves, diagnostic calibration curves, and decision curve analysis (DCA) curves. Furthermore, clinical data from 100 additional cases of MP-positive lobar pneumonia in children treated at other centers were gathered for external validation of the model.

Results Binary logistic regression analysis identified four independent risk factors for prolonged disease duration in children with MP-positive lobar pneumonia: erythrocyte sedimentation rate (ESR), globulin, lactate dehydrogenase (LDH), and SF. We constructed a nomogram model based on these risk factors. In the training set, the area under the curve (AUC) was 0.869 (95% CI: 0.822–0.917), with a sensitivity of 68.54% and a specificity of 82.61%. For the test set, the AUC increased to 0.918 (95% CI: 0.866–0.971), demonstrating a sensitivity of 91.67% and a specificity of 78.69%. The DeLong test results indicated that the difference in AUC between the two datasets was not statistically significant (D = − 1.724, p = 0.086). Calibration curve analysis confirmed that the nomogram model exhibited a good fit in both the training set (Hosmer–Lemeshow test, χ2 = 8.120, p = 0.421) and the validation set (Hosmer–Lemeshow test, χ2 = 14.601, p = 0.067). DCA further demonstrated that the model performed significantly across a range of threshold probabilities.

Conclusion The nomogram model developed for predicting refractory MP-positive lobar pneumonia in children has significant clinical value and can guide personalized treatment strategies.

Keywords

model - MP - refractory - lobar pneumonia - pediatric

* These authors contributed equally to this work.


Supplementary Material



Publication History

Received: 07 August 2024

Accepted: 07 November 2024

Article published online:
24 December 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Leng J, Yang Z, Wang W. Diagnosis and prognostic analysis of Mycoplasma pneumoniae pneumonia in children based on high-resolution computed tomography. Contrast Media Mol Imaging 2022; 2022: 1985531
    CrossrefPubMedSearch in Google Scholar
  • 2 Lanata MM, Wang H, Everhart K, Moore-Clingenpeel M, Ramilo O, Leber A. Macrolide-resistant Mycoplasma pneumoniae infections in children, Ohio, USA. Emerg Infect Dis 2021; 27 (06) 1588-1597
    CrossrefPubMedSearch in Google Scholar
  • 3 Kamidani S, Rostad CA, Anderson EJ. COVID-19 vaccine development: a pediatric perspective. Curr Opin Pediatr 2021; 33 (01) 144-151
    CrossrefPubMedSearch in Google Scholar
  • 4 Tong L, Huang S, Zheng C, Zhang Y, Chen Z. Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management. J Clin Med 2022; 11 (10) 2824
    CrossrefPubMedSearch in Google Scholar
  • 5 Meyer Sauteur PM, Beeton ML. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe 2024; 5 (02) e100-e101
    CrossrefPubMedSearch in Google Scholar
  • 6 Liu TY, Lee WJ, Tsai CM. et al. Serum lactate dehydrogenase isoenzymes 4 plus 5 is a better biomarker than total lactate dehydrogenase for refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Neonatol 2018; 59 (05) 501-506
    CrossrefPubMedSearch in Google Scholar
  • 7 Zhao SY, Liu HM, Lu Q. et al. Interpretation of key points in diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (November 2023) [in Chinese]. Zhonghua Er Ke Za Zhi 2024; 62 (02) 108-113
    PubMedSearch in Google Scholar
  • 8 National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023 edition) [in Chinese]. Inter J Epidemiol Infect Dis 2023; 50 (02) 79-85
    PubMedSearch in Google Scholar
  • 9 Mirchandani LV, Kamath SS, Kutty JT, Iyer A. Epituberculosis revisited: case report and review. J Clin Diagn Res 2017; 11 (09) OD05-OD07
    PubMedSearch in Google Scholar
  • 10 Shi S, Zhang X, Zhou Y, Tang H, Zhao D, Liu F. Immunosuppression reduces lung injury caused by Mycoplasma pneumoniae infection. Sci Rep 2019; 9 (01) 7147
    CrossrefPubMedSearch in Google Scholar
  • 11 Akkiz H, Carr BI, Bag HG. et al. Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma. Int J Clin Pract 2021; 75 (02) e13593
    CrossrefPubMedSearch in Google Scholar
  • 12 Zhou Y, Qi M, Yang M. Current status and future perspectives of lactate dehydrogenase detection and medical implications: a review. Biosensors (Basel) 2022; 12 (12) 1145
    CrossrefPubMedSearch in Google Scholar
  • 13 Fan F, Lv J, Yang Q, Jiang F. Clinical characteristics and serum inflammatory markers of community-acquired mycoplasma pneumonia in children. Clin Respir J 2023; 17 (07) 607-617
    CrossrefPubMedSearch in Google Scholar
  • 14 Jing XY, Lu M. Risk factor analysis about severe Mycoplasma pneumoniae pneumonia in children. Shanghai Med J 2019; 42 (01) 27-31
    PubMedSearch in Google Scholar
  • 15 Chen Q, Hu T, Wu L, Chen L. Clinical features and biomarkers for early prediction of refractory Mycoplasma pneumoniae pneumonia in children. Emerg Med Int 2024; 2024: 9328177
    CrossrefPubMedSearch in Google Scholar
  • 16 Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta 2010; 1800 (08) 760-769
    CrossrefPubMedSearch in Google Scholar
  • 17 Zhang X, Sun R, Jia W, Li P, Song C. Clinical characteristics of lung consolidation with Mycoplasma pneumoniae pneumonia and risk factors for Mycoplasma pneumoniae necrotizing pneumonia in children. Infect Dis Ther 2024; 13 (02) 329-343
    CrossrefPubMedSearch in Google Scholar
  • 18 Ling Y, Zhang T, Guo W. et al. Identify clinical factors related to Mycoplasma pneumoniae pneumonia with hypoxia in children. BMC Infect Dis 2020; 20 (01) 534
    CrossrefPubMedSearch in Google Scholar
  • 19 Choi YJ, Jeon JH, Oh JW. Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: a case control study. Respir Res 2019; 20 (01) 193
    CrossrefPubMedSearch in Google Scholar
  • 20 Lai WC, Hsieh YC, Chen YC. et al. A potent antibody-secreting B cell response to Mycoplasma pneumoniae in children with pneumonia. J Microbiol Immunol Infect 2022; 55 (03) 413-420
    CrossrefPubMedSearch in Google Scholar
  • 21 Chaudhry R, Ghosh A, Chandolia A. Pathogenesis of Mycoplasma pneumoniae: an update. Indian J Med Microbiol 2016; 34 (01) 7-16
    CrossrefPubMedSearch in Google Scholar
  • 22 Wang J, Guo C, Yang L, Sun P, Jing X. Peripheral blood microR-146a and microR-29c expression in children with Mycoplasma pneumoniae pneumonia and its clinical value. Ital J Pediatr 2023; 49 (01) 119
    CrossrefPubMedSearch in Google Scholar
  • 23 Jin Y, Xue J, Ruan M. et al. Expression of serum miR-155 in children with Mycoplasma pneumoniae pneumonia and its role in immunity to Mycoplasma pneumoniae . Infect Drug Resist 2021; 14: 1273-1281
    CrossrefPubMedSearch in Google Scholar
  • 24 Jia Z, Sun Q, Zheng Y, Xu J, Wang Y. The immunogenic involvement of miRNA-492 in mycoplasma pneumoniae infection in pediatric patients. J Pediatr (Rio J) 2023; 99 (02) 187-192
    CrossrefPubMedSearch in Google Scholar
  • 25 Lee YC, Chang CH, Lee WJ. et al. Altered chemokine profile in refractory Mycoplasma pneumoniae pneumonia infected children. J Microbiol Immunol Infect 2021; 54 (04) 673-679
    CrossrefPubMedSearch in Google Scholar